Extravasated platelet aggregation in liver zone 3 may correlate with the progression of sinusoidal obstruction syndrome following living donor liver transplantation: A case report

Experimental and Therapeutic Medicine

Volumn 9, Issue 4, 2015, Pages 1119-1124

  Nakanuma, Shinichi ^a   Miyashita, Tomoharu ^a   Hayashi, Hironori ^a   Tajima, Hidehiro ^a   Takamura, Hiroyuki ^a   Tsukada, Tomoya ^a   Okamoto, Koichi ^a   Sakai, Seisho ^a   Makino, Isamu ^a   Kinoshita, Jun ^a   Nakamura, Keishi ^a   Oyama, Katsunobu ^a   Inokuchi, Masafumi ^a   Nakagawara, Hisatoshi ^a   Ninomiya, Itasu ^a   Kitagawa, Hirohisa ^a   Fushida, Sachio ^a   Fujimura, Takashi ^a   Ohta, Tetsuo ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

Aggregation; Cluster of differentiation 42b; Liver transplantation; Platelet; Sinusoidal obstruction syndrome; Veno occlusive disease

Indexed keywords

BILIRUBIN; GLYCOPROTEIN IB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ADULT; ARTICLE; BLOOD ANALYSIS; CASE REPORT; CELL DIFFERENTIATION; DISEASE COURSE; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; LIVER BIOPSY; LIVER TRANSPLANTATION; LIVER VENOOCCLUSIVE DISEASE; MALE; MIDDLE AGED; POSTOPERATIVE PERIOD; THROMBOCYTE AGGREGATION; TREATMENT OUTCOME;

EID: 84923061884     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2015.2245     Document Type: Article

References (33)

1. Kitajima K, Vaillant JC, Charlotte F, et al: Intractable ascites without mechanical vascular obstruction after orthotopic liver transplantation: etiology and clinical outcome of sinusoidal obstruction syndrome. Clin Transplant 24: 139-148, 2010.
2. Campos Varela I, Castells L, Dopazo C, et al: Transjugular intrahepatic portosystemic shunt for the treatment of sinusoidal obstruction syndrome in a liver transplant recipient and review of the literature. Liver Transpl 18: 201-205, 2012.
3. Membreno FE, Ortiz J, Foster PF, Wright F, et al: Liver transplantation for sinusoidal obstructive syndrome (veno occlusive disease): case report with review of the literature and the UNOS database. Clin Transplant 22: 397-404, 2008.
4. Sebagh M, Debette M, Samuel D, et al: 'Silent' presentation of veno occlusive disease after liver transplantation as part of the process of cellular rejection with endothelial predilection. Hepatology 30: 1144-1150, 1999.
5. Coppell JA, Brown SA and Perry DJ: Veno occlusive disease: cytokines, genetics, and haemostasis. Blood Rev 17: 63-70, 2003.
6. Pihusch V, Pihusch M, Penovici M, et al: Transforming growth factor beta 1 released from platelets contributes to hypercoagulability in veno occlusive disease following hematopoetic stem cell transplantation. Thromb Res 116: 233-240, 2005.
7. Salat C, Holler E, Kolb HJ, et al: Plasminogen activator inhibitor 1 confirms the diagnosis of hepatic veno occlusive disease in patients with hyperbilirubinemia after bone marrow transplantation. Blood 89: 2184-2188, 1997.
8. Oh H, Tahara T, Bouvier M, et al: Plasma thrombopoietin levels in marrow transplant patients with veno occlusive disease of the liver. Bone Marrow Transplant 22: 675-679, 1998.
9. Wiesner RH, McDiarmid SV, Kamath PS, et al: MELD and PELD: application of survival models to liver allocation. Liver Transpl 7: 567-580, 2001.
10. Chen H, Wang X, Fan T, et al: A case of veno occlusive disease following liver transplantation. Exp Ther Med 7: 141-144, 2014.
11. Wang SE, Shyr YM and Lee RC: Hepatic veno occlusive disease related to tacrolimus after pancreas transplantation. J Chin Med Assoc 76: 358-360, 2013.
12. Shulman HM, Gown AM and Nugent DJ: Hepatic veno occlusive disease after bone marrow transplantation. Immunohistochemical identification of the material within occluded central venules. Am J Pathol 127: 549-558, 1987.
13. Cogger VC, McNerney GP and Nyunt T: Three-dimensional structured illumination microscopy of liver sinusoidal endothelial cell fenestrations. J Struct Biol 171: 382-388, 2010.
14. Mak KM and Lieber CS: Alterations in endothelial fenestrations in liver sinusoids of baboons fed alcohol: a scanning electron microscopic study. Hepatology 4: 386-391, 1984.
15. Yamamoto M, Sumiyoshi H, Nakagami K and Tahara E: Distribution of collagen types I, III, and V in fibrotic and neoplastic human liver. Acta Pathol Jpn 34: 77-86, 1984.
16. Jung SM, Takemura Y, Imamura Y, et al: Collagen type specificity of glycoprotein VI as a determinant of platelet adhesion. Platelets 19: 32-42, 2008.
17. Brech A, Kjeken R, Synnes M, et al: Endocytosed ricin and asialoorosomucoid follow different intracellular pathways in hepatocytes. Biochim Biophys Acta 1373: 195-208, 1998.
18. Steirer LM, Park EI, Townsend RR, et al: The asialoglycoprotein receptor regulates levels of plasma glycoproteins terminating with sialic acid alpha2, 6-galactose. J Biol Chem 284: 3777-3783, 2009.
19. Sørensen AL, Rumjantseva V, Nayeb Hashemi S, et al: Role of sialic acid for platelet life span: exposure of beta galactose results in the rapid clearance of platelets from the circulation by asialoglycoprotein receptor expressing liver macrophages and hepatocytes. Blood 114: 1645-1654, 2009.
20. Golebiewska EM and Poole AW: Platelet secretion: From haemostasis to wound healing and beyond. Blood Rev: Oct 31, 2014 (Epub ahead of print), doi: 10. 1016/j. blre. 2014. 10. 003.
21. Mohammad SF, Anderson WH, Smith JB, et al: Effects of heparin on platelet aggregation and release and thromboxane A2 production. Am J Pathol 104:132-141, 1981.
22. Anitua E, Andia I, Ardanza B, et al: Autologous platelets as a source of proteins for healing and tissue regeneration. Thromb Haemost 91:4-15, 2004.
23. Ruan Z, Shibamoto T, Shimo T, et al: Effects of platelet activating factor and thromboxane A2 on isolated perfused guinea pig liver. Prostaglandins Other Lipid Mediat 73: 73-85, 2004.
24. Parenti A, Brogelli L, Filippi S, et al: Effect of hypoxia and endothelial loss on vascular smooth muscle cell responsiveness to VEGF A: role of flt 1/VEGF receptor 1. Cardiovasc Res 55: 201-212, 2002.
25. Ribero D, Wang H, Donadon M, et al: Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin based chemotherapy for colorectal liver metastases. Cancer 110: 2761-2767, 2007.
26. Mars WM, Zarnegar R and Michalopoulos GK: Activation of hepatocyte growth factor by the plasminogen activators uPA and tPA. Am J Pathol 143: 949-958, 1993.
27. Watanabe K, Togo S, Takahashi T, et al: PAI 1 plays an important role in liver failure after excessive hepatectomy in the rat. J Surg Res 143: 13-19, 2007.
28. Ueda S, Yamanoi A, Hishikawa Y, et al: Transforming growth factor beta1 released from the spleen exerts a growth inhibitory effect on liver regeneration in rats. Lab Invest 83: 1595-1603, 2003.
29. Watanabe T, Tajima H, Hironori H, et al: Sodium valproate blocks the transforming growth factor (TGF) β1 autocrine loop and attenuates the TGF β1 induced collagen synthesis in a human hepatic stellate cell line. Int J Mol Med 28: 919-925, 2011.
30. Yamada N, Urahashi T, Ihara Y, et al: Veno occlusive disease/sinusoidal obstruction syndrome associated with potential antibody mediated rejection after pediatric living donor liver transplantation: a case report. Transplant Proc 44: 810-813, 2012.
31. Zhang L, Wang Y and Huang H: Defibrotide for the prevention of hepatic veno occlusive disease after hematopoietic stem cell transplantation: a systematic review. Clin Transplant 26: 511-519, 2012.
32. Iba T, Kidokoro A, Fukunaga M, et al: Comparison of the protective effects of type III phosphodiesterase (PDE3) inhibitor (cilostazol) and acetylsalicylic acid on intestinal microcirculation after ischemia reperfusion injury in mice. Shock 26: 522-526, 2006.
33. Wang S, Yan C, Xu H, Zhao X and Han Y: Suppression of encephalitogenic T cell responses by cilostazol is associated with upregulation of regulatory T cells. Neuroreport 21: 629-635, 2010.